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Abstract  
Introduction: Preterm birth (PTB) is a major cause of neonatal morbidity and mortality. Pregnant 
woman is one of the most vulnerable groups for vitamin D deficiency, that increase the risk of PTB. 
Vitamin D has the role of immunomodulator, anti-inflammatory, and transcription of genes 
involved in placental function. Research results on the correlation between vitamin D 
supplementation and PTB risk are still inconsistent. 
Objectives: To observe the effect of oral vitamin D supplementation during pregnancy on the risk 
of PTB  
Methods: Advanced search for relevant literatures in PubMed, Cochrane, and Willey was 
conducted. After assessing the relevancy and eligibility, articles were selected and critically 
appraised. 
Results: There were three articles that relevant with the eligibility criteria and clinical questions, 
they were randomized controlled trial, meta-analysis and systematic review. Three studies found 
that oral vitamin D supplementation in the form of cholecalciferol during pregnancy had a 
significant reduction on the risk of PTB. A systematic review found that supplementation with 
combination of cholecalciferol and calcium carbonate may increase the risk of PTB. The different 
dosages, frequencies, and time of initiation limit the generalizations for efficacy and safety doses. 
Conclusions: Oral cholecalciferol supplementation during pregnancy reduces the risk of PTB. While 
supplementation with combination of cholecalciferol and calcium carbonate requires 
consideration. Research on the effect of oral vitamin D supplementation during pregnancy on the 
risk of PTB is still limited and need for more studies. Recommendation for vitamin D consumption 
based on the RDA needs to be fulfilled in pregnant women. 




Preterm birth (PTB) is defined as birth that occurs 
between 20 to 37 weeks of pregnancy. The rate 
ranges from 5% to 18% of babies born. Every year 
an estimated 15 million babies are born prematurely, 
increasing in most countries and becoming a global 
issues.1–3 In 2017, 5.4 million children under 5 years 
old died and PTB complications are the leading 
cause of their deaths.1,4 According to WHO, 
Indonesia is the ninth country with the highest PTB 
rate, which is 15.5 per 100 live births. Also the fifth 
country with the greatest number of PTB, which is 
675,700 births.1 
Preterm babies may be born with serious health 
problems, include motor and cognitive 
neurodevelopmental disabilities (cerebral palsy, 
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blindness, deafness, mental retardation, and learning 
disabilities), chronic lung disease and 
gastrointestinal problems.2,5,6 PTB is associated with 
a 3 to 4-fold higher incidence of adverse maternal 
outcomes including the need for blood transfusion 
and prolonged hospitalization, and increased 
frequency of cesarean births more than doubled.7 
There are several common cause of PTB, 
inflammation and infection are highly significant 
risk factors.1,2,5 Vitamin D is suggested to influence 
physiological pathways involved in PTB, including 
inflammation, immunomodulation, and transcription 
of genes involved in placental function.8–10 Vitamin 
D has the effect of suppressing some inflammatory 
cytokines. Vitamin D receptors are present in 
immune cells, which produce antimicrobial peptides 
and prevent perinatal infections.10 Poor maternal 
nutrition at preconception and during early 
pregnancy also affect the risk of PTB.8 Pregnant 
women is one of the most vulnerable groups for 
vitamin D deficiency.11 Research has suggested that 
maternal vitamin D deficiency, or insufficiency, has 
related to several adverse maternal and fetal 
outcomes, including preterm labor (PTL) or PTB.6,11 
There have been several studies that describe the 
relationship between vitamin D supplementation 
and PTB, however, the results were inconsistent. 
Mojibian M., et al.,12 showed that consumption of 
50,000 IU vitamin D every 2 weeks from 12 weeks 
of pregnancy until delivery the incidence of PTL 
were not significantly different. Meanwhile, Persad 
MD., et al.,13 showed that vitamin D 
supplementation was associated with the prevention 
of PTB (RR 0.54; 95% CI 0.42-0.68). Therefore, the 
aim of this study to analyze the effect of oral vitamin 




Can vitamin D supplementation during pregnancy 
reduce the risk of having preterm birth? 
P: Pregnant women 
I:  Oral vitamin D supplementation 
C: Placebo or without vitamin D supplementation 




Strategy of article searching 
Advanced searching was used for this literature 
searching from three main databases: PubMed, 
Cochrane, and Willey on May 15th, 2020 (Table 1) 
 




The article was selection based on the inclusion and 
exclusion criteria. Inclusion criteria were: (1) 
Pregnant women, (2) Oral vitamin D 
supplementation, (3) Comparison with placebo or 
without vitamin D supplementation, (4) Preterm 
birth or preterm labor as the study outcome, (5) 
Systematic review of randomized controlled trial 
(RCT), meta-analysis or RCT (6) Publication within 
the last 5 years. Exclusion criteria were: (1) Not in 
accordance with the clinical question, (2) There is no 
full text available, (3) Article is not written in 
English. 
 
Method of Critical Appraisal 
 
Articles were reviewed by all authors using the 
critical appraisal method according to the Center of 
Evidence-Based Medicine for therapy studies. 
Critical appraisal was done on the articles, so that 
the validity, importance and applicability could be 
assessed. The level of evidence in this study was 
determined based on the Oxford Center for 
Evidence-based Medicine – Levels of Evidence. 
 
Results 
Following of the search strategy, three original 
articles were eligible for this evidence-based case 
report (Figure 1). The first study was a RCT with 
level of evidence of 2, the second study was a 
systematic review with level of evidence of 1, the 
third study was a meta-analysis with level of 
evidence of 1. Characteristics of the studies are 
shown in Table 2. Critical appraisal was carried out 





The first study by Sablok A., et al.,11 that conducted 
a randomized controlled trial (RCT) to 180 
primigravidae with singleton pregnancy at 14-20 
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weeks. Participants were divided into two groups, 
group A formed the non-intervention group whereas 
group B formed the cholecalciferol supplementation 
group, with a dose dependent on the estimated 25-
OHD serum level at baseline. One of the risk of 
maternal complications as outcome of this study was 
PTL or PTB. The result of this study was 21.1% of 
the patients in group A had PTB compared to 8.3% 
in group B, a significant decrease in incidence of 
PTB in the supplementation group (p=0.02).11 
The second study is a systematic review by Luz 
Maria D., et al.,14 that included 15 RCTs involving 
2833 pregnant women. One of the primary outcome 
of this study was to determine whether oral vitamin 
D supplementation alone or in combination with 
calcium or other vitamins and minerals can reduce 
the risk of PTB. This study method was based on a 
standard template used by Cochrane Pregnancy and 
Childbirth. GRADE was used to assess the quality 
of evidence and the strength of recommendations. 
As only one study was considered of high quality, 
sensitivity analyzes in this study was not 
conducted.14 
Oral vitamin D supplementation in the form of 
cholecalciferol during pregnancy reduces the risk of 
PTB compared to no intervention or placebo (RR 
0.36, 95% CI 0.14 to 0.93; 3 trials, 477 women, 
moderate quality). Only one reported case of 
nephritic syndrome in the control group in one study 
(RR 0.17, 95% CI 0.01 to 4.06; 1 trial, 135 women, 
low quality). Due to limitations of data for maternal 
adverse events, no conclusions could be drawn.14 
Oral supplementation with combination of 
vitamin D (cholecalciferol) and calcium (calcium 
carbonate) increased the risk of PTB compared to no 
treatment or placebo (RR 1.57, 95% CI 1.02 to 2.43; 
3 trials, 798 women, moderate quality). No trial 
reported on maternal adverse events in 
supplementation with combination of vitamin D and 
calcium. There were no studies included in 
supplementation with combination of vitamin D and 
calcium compared to supplementation with calcium 
(without vitamin D), and supplementation with 
combination of vitamin D, calcium and other 
vitamins and minerals.14 
The third study is a meta-analysis by Zhou S., et 
al,15 that included six RCTs and 18 observational 
studies. The six RCTs in this study investigated 
whether vitamin D supplementation during 
pregnancy can reduce the risk of PTB. The risk for 
PTB among women receiving supplement ranged 
from 0.06 to 1.20, and positive and significant 
results were reported in one out of the six RCTs. 
Three RCTs had a low risk of bias, one had a 
moderate risk of bias, and two had a high risk of 
bias.15 
Vitamin D3 dosage used for the intervention 
groups ranged from a daily dosage of 400 IU to 
multiple bolus dosage of 120,000 IU. The result of 
meta-analysis in six RCTs involved 1687 pregnant 
women was RR=0.57 (95%CI: 0.36–0.91) and test 
of heterogeneity, I²=26.2% (p=0.238), suggested 
that women who received vitamin D3 
supplementation during pregnancy had a lower risk 
of PTB compared to women who received placebo 
or routine antenatal care. In the subgroup analysis of 
RCT, the studies with sample size >100, low risk of 
bias and single-dose supplementation of vitamin D3, 
could reduce the risk of PTB, but no conclusions 
could be drawn because the subgroups had only one 
or two RCTs, and the results may be misleading. 
RCT sensitivity analysis showed that there were two 
studies that significantly influence the results. The 
small sample size produced unstable results, 
therefore it was difficult to exclude the possibility 
that the positive association was due to chance.15 
 This meta-analysis tried to explain the effect of 
vitamin D on PTB risk. The possible protective 
effect of vitamin D against PTB by reducing 
infection and inflammation, as the major cause of 
PTB. Maternal serum 25-OHD and 1,25-diOHD 
also can inhibit inflammatory factors, such as tumor 
necrosis factor-α and interleukin 6, while at the same 
time promoting anti inflammatory cytokine and 
cathelicidin, responding to microbial invasion 
through activation of toll-like receptors on 
monocytes and macrophages. Vitamin D may also 
affect placental function, given that 1,25-
dihydroxyvitamin D3 can reduce oxidative stress, 
which is associated with iatrogenic PTB.15 
Limitations of intervention studies in this meta-
analysis were inconsistent dosage regimen, timing 
of initiation and quality of design were limited the 
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Conclusion 
 
All three studies, RCT, meta-analysis and systematic 
review, found that oral vitamin D supplementation 
in the form of cholecalciferol during pregnancy had 
a significant reduction on the risk of PTB. A 
systematic review found that oral supplementation 
with combination of cholecalciferol and calcium 
carbonate may increase the risk of PTB. The 
different dosages, frequencies, and time of initiation 
limit the generalizations for efficacy and safety 
doses. Due to limited data for maternal adverse 
events, no conclusions can be drawn. Research on 
the effect of oral vitamin D supplementation during 
pregnancy on the risk of PTB is still limited and need 
for more studies. Recommendation for vitamin D 
consumption based on the RDA needs to be fulfilled 



















Table 1. Resources and search strategy  
 
Database Search strategy Hits Selected 
Article 
PubMed ((((("pregnancy"[Title/Abstract] AND ("vitamin D"[Title/Abstract] OR 
"vitamin D supplementation"[Title/Abstract])) AND (("preterm 
birth"[Title/Abstract] OR "preterm labor"[Title/Abstract]) OR 
"premature birth"[Title/Abstract])) AND 2015/5/15:3000/1/1[Date - 
Publication]) AND ("systematic"[Filter] AND 2015/5/15:3000/1/1[Date 
- Publication])) AND (("meta-analysis"[Publication Type] OR 
"systematic"[Filter]) AND 2015/5/15:3000/1/1[Date - Publication])) 
AND ((("clinical trial"[Publication Type] OR "meta-
analysis"[Publication Type]) OR "systematic"[Filter]) AND 
2015/5/15:3000/1/1[Date - Publication]) 
 
16 1 
Cohrane ID Search 
#1 “pregnancy” 
#2    "vitamin D" OR "vitamin D supplementation" OR 
"cholecalciferol’ OR "ergocalciferol’ 
#3 "preterm birth" OR "preterm labor" OR "premature birth" 
#4    #1 AND #2 AND #3 with Cochrane Library publication date 
Between May 2015 and May 2020, in Cochrane Reviews, Trials 
 
65 1 
Wiley  search result for [[All: "vitamin d"] OR [All: "vitamin d 
supplementation"] OR [All: "cholecalciferol’ or "]] AND [All: 
ergocalciferol’] AND [[All: "preterm birth"] OR [All: "preterm labor"] 













• Pregnant women 
• Oral vitamin D 
supplementation 
• Comparison with placebo or 
without vitamin D 
supplementation 
• Preterm birth or preterm 
labor as the study outcome 
• Systematic review of RCT, 
Meta-analysis, or RCT 
• Publication within the last 5 
years 
• Excluded because of the 
different at : 
- Population (n=11) 
- Intervention or control 
(n=44) 
- Outcome (n=17) 
- Study design (n=19) 
• Non-English articles 
(n=0) 
• Full text not available 
(n=6) 
“pregnancy” AND "vitamin D OR vitamin D supplementation OR cholecalciferol OR 
ergocalciferol” AND "preterm birth OR preterm labor OR premature birth" 














Figure 1. PRISMA flow chart 
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Group B (n=120), 
classified as: 
- Sufficient levels 
of VD (> 
50nmol/L) 
received one 








doses of 120 000 
IU at 20 and 24 
weeks 
- Deficient levels 
(<25nmol/L) 
received four 
doses of 120 000 
IU at 20, 24, 28 





- Risk of maternal 
complications: PTL, 
pre-eclampsia and 
GDM associated with 
VD deficiency  
 
- Infants of mothers with 
VD deficiency: LBW 























- VD + Ca 
- VD + Ca + VM 
 
VD varied in 
dosage, regimen 






(3 trials), and no 
report (2 trials).  
 
VD daily dose: 
200 IU – 2000 IU 
 
(to be continued in 




- Ca + 
VM 
- VM 
- Primary outcomes: 
Pre-eclampsia, GDM, 
VD concentration at 
term, adverse effects 
(hypercalcaemia, 
kidney stones), PTB 
(<37 weeks' gestation), 
LBW (< 2500 g). 
 
- Secondary outcomes: 
Impaired glucose 
tolerance, caesarean 
section, GH, maternal 
death, birth length, 
head circumference, 
birth weight, admission 
to special care during 
the neonatal period, 
stillbirth, neonatal 
death, Apgar score, 
neonatal infection, very 
PTB (< 32 weeks' 
gestation) 
 
    -  -  -  
 



































































   (continued) 
 
VD single‐dose: 
200,000 IU, 600,000 
IU, 35,000 IU per 
week and dose 
depended upon the 
level of serum 25-
OHD levels at 
baseline  
 
VD time to start: ≥ 




Ca carbonate, doses 
ranged from 375 mg 




Iron (60 mg ferrous 
sulphate) 



















VD3 dosage ranged 
from 400 IU daily to 
multiple bolus 






mg and Ca 
600 mg 
daily, but no 
VD) 
 
- Association between 
maternal circulating 25-
OHD and the risk of 
PTB or sPTB 
- Effect of VD 
supplementation during 
pregnancy on reduce the 
risk of PTB 
 
RCT = Randomized Controlled Trial; IU = International Unit; 25-OHD = 25 hydroxyvitamin D; GDM = Gestational 
Diabetes; LBW = Low Birth Weight; PTB = Preterm Birth; sPTB = Spontaneous Preterm Birth; PTL = Preterm Labor; 
GH = Gestational Hypertension; VD = Vitamin D; VD3 = Vitamin D3; Ca = Calcium; VM = Vitamin and Mineral; NI = 
No Intervention. 
 





Table 3. Critical appraisal of the RCT study 
 
Parameters  Question  Sablok A., et al.11  
(2015) 
VALIDITY Was the assignment of patient to treatments randomized? Yes 
 
 Were the groups similar at the start of the trial? Not Clear 
 
 Aside from the allocated treatment, were groups treated 
equally? 
No 
 Were all patients who entered the trial accounted for?   No 
 And were they analyzed in the group to which they were 
randomized? 
Yes 
 Were measures objective or were the patients and 
clinicians kept “blind” to which treatment was being 
received? 
Not clear 
IMPORTANCE How large was the treatment effect? p= 0.02 
 How precise was the estimate of the treatment effect? Precise, the 95% CI of the 
results are narrow 
APPLICABILITY Is my patient so different to those in the study that the 
results cannot apply? 
No 
 Is the treatment feasible in my setting? Yes 
 Will the potential benefit of treatment outweigh the 
potential harms of treatment for my patient? 
Yes 
 
Table 4. Critical appraisal of systematic review and meta-analysis 
 
Parameters  Question  Luz Maria D., et al.14  
(2016) 
Zhou S., et 
al.15 
(2017) 
VALIDITY Did the meta-analysis address a focused 
question (PICO)? 
Yes Yes 
 Does the meta-analysis use it to direct the 
search and select articles for inclusion?  
Yes Yes 
 Did the search find all the relevant evidence?  Yes Yes 
 Have the studies been critically appraised?  Yes Yes 
 Did they only include high quality studies?  No No 
 Have the results been totalled up with 
appropriate summary tables and plots?  
Yes Yes 
 And heterogeneity between studies assessed 
and explained? 
Yes Yes 
IMPORTANCE Was measure clearly explained?  
How are the results presented? 
Yes 
 







Figure 1-7 and 
Summary of 
findings 
APPLICABILITY Can we apply this valid, important evidence 
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